A detailed history of Virtus ETF Advisers LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 5,512 shares of NRIX stock, worth $109,302. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,512
Previous 5,411 1.87%
Holding current value
$109,302
Previous $112,000 9.82%
% of portfolio
0.06%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.93 - $25.69 $1,911 - $2,594
101 Added 1.87%
5,512 $123,000
Q2 2024

Aug 14, 2024

SELL
$12.02 - $21.3 $51,469 - $91,206
-4,282 Reduced 44.18%
5,411 $112,000
Q1 2024

May 15, 2024

SELL
$7.77 - $15.66 $5,151 - $10,382
-663 Reduced 6.4%
9,693 $142,000
Q4 2023

Feb 15, 2024

BUY
$4.25 - $10.71 $5,716 - $14,404
1,345 Added 14.93%
10,356 $106,000
Q3 2023

Nov 07, 2023

SELL
$7.86 - $10.08 $7,081 - $9,082
-901 Reduced 9.09%
9,011 $70,000
Q2 2023

Aug 14, 2023

BUY
$8.7 - $13.28 $15,059 - $22,987
1,731 Added 21.16%
9,912 $99,000
Q1 2023

May 15, 2023

SELL
$8.56 - $13.26 $26,972 - $41,782
-3,151 Reduced 27.81%
8,181 $72,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $14.59 $5,117 - $7,572
519 Added 4.8%
11,332 $124,000
Q3 2022

Nov 14, 2022

BUY
$12.33 - $19.81 $961 - $1,545
78 Added 0.73%
10,813 $141,000
Q2 2022

Aug 12, 2022

BUY
$7.88 - $14.82 $39,864 - $74,974
5,059 Added 89.13%
10,735 $136,000
Q1 2022

May 16, 2022

SELL
$12.94 - $29.65 $4,321 - $9,903
-334 Reduced 5.56%
5,676 $80,000
Q4 2021

Feb 14, 2022

SELL
$26.43 - $34.5 $31,266 - $40,813
-1,183 Reduced 16.45%
6,010 $174,000
Q3 2021

Nov 15, 2021

SELL
$22.71 - $36.69 $8,561 - $13,832
-377 Reduced 4.98%
7,193 $216,000
Q2 2021

Aug 10, 2021

BUY
$24.21 - $35.89 $183,269 - $271,687
7,570 New
7,570 $201,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.